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Nail psoriasis, aﬀecting up to 50% of psoriatic patients, is an important cause of serious psychological and physical distress.
Traditional treatments for nail psoriasis, which include topical or intralesional corticosteroids, topical vitamin D analogues,
photochemotherapy, oral retinoids, methotrexate, and cyclosporin, can be time-consuming, painful, or limited by signiﬁcant
toxicities. Biological agents may have the potential to revolutionize the management of patients with disabling nail psoriasis. We
present another case of disabling nail psoriasis that responded dramatically to inﬂiximab.
1.Introduction
Nail psoriasis, aﬀecting up to 50% of psoriatic patients, is an
important cause of distress, impairment of manual dexterity,
and pain [1]. Nail involvement varies from pitting to nail
dystrophy. Psoriatic nail disease is a therapeutic challenge,
andtodate,patientsandphysiciansareoftendissatisﬁed with
current standard therapeutic approaches. Inﬂiximab, which
is approved for the treatment of moderate to severe plaque
psoriasis and psoriatic arthritis, is a chimeric monoclonal
antibody that inhibits the action of tumour necrosis factor
alpha (TNFα). Several reports have conﬁrmed its usefulness
in treating nail psoriasis [2]. The present paper describes
another case of disabling nail psoriasis that responded
dramatically to inﬂiximab.
2.CasePresentation
A34-year-old farmer with ahistory ofstable localized plaque
psoriasis was referred to our department with psoriatic
nail disease involving four ﬁngernails. The toenails did not
show any signiﬁcant lesions, and no symptoms of psoriatic
arthritis were noted. He had previously been prescribed
topical treatments, including potent topical corticosteroids
and vitamin D3 analogs, without any eﬃcacy. The patient’s
discomfort was aﬀecting his ability to work and his qualityof
life because of psychosocial impairments. On examination,
subungual hyperkeratosis, pitting, and onycholysis were seen
in four ﬁngernails (Figures 1(a) and 1(b)). Because of the
presence of disabling symptoms in this patient, acitretin
(25mg daily) was initially started, but this drug proved in-
eﬀective after 6 months of therapy.
After screening for infection, neoplasm, and autoimmu-
nity, all of which were negative, the patient was started on
inﬂiximab at a dose of 5mg/kg administered at weeks 0, 2,
and 6. A dramatic improvement was noticed after the second
infusion ofinﬂiximab atweek6(Figure2).Thepatient’snails
remained free of psoriatic lesions after the third infusion.
This treatment regimen was followed by a single infusion
every 8 weeks for maintenance therapy.
3.Discussion
Biological agents have demonstrated eﬃcacy for the treat-
ment of plaque psoriasis and psoriatic arthritis and are now
widely used. Even if the severity of psoriatic skin lesions
remains the primary reason to start biological treatments,
nail psoriasis should be considered a valid reason to start
these therapies because of its large impact on daily living
activities and quality of life. Furthermore, nail psoriasis can
be a predictor of future inﬂammatory joint damage, a pre-
cursor of psoriatic arthritis, and a visible indicator of disease
activity [3]. There are currently no standardized therapeutic
regimens for nail psoriasis. Traditional treatments for nail2 Case Reports in Medicine
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Figure 1: Subungual hyperkeratosis, pitting, and onycholysis of
right-hand ﬁngernails 3, 4, and 5 (a) and of left-hand ﬁngernail 2
(b).
Figure 2: Fingernails after the second infusion of inﬂiximab.
psoriasis, which include topical or intralesional corticos-
teroids, topical vitamin D3 analogues, photochemotherapy,
oral retinoids, methotrexate, and cyclosporin, can be time-
consuming, painful, or limited by signiﬁcant toxicities [4].
Biological agents that target cytokines may have the po-
tential to revolutionize the management of patients with dis-
abling nail psoriasis. These agents include anti-TNFα agents
such as inﬂiximab, adalimumab, and etanercept, and anti-
interleukin (IL)-12/-23, the ﬁrst drug of a new class of bio-
therapy agents.
Adalimumabisa fullyhuman anti-TNFαantibody thatis
administered subcutaneouslyevery2 weeks. Ina prospective,
open-label, uncontrolled study conducted in nine European
countries, patients with active psoriatic arthritis received
adalimumab 40mg every other week for 12 weeks in addi-
tion to their pre-existing antirheumatic treatment. Of 442
patients, 259 had nail involvement. After the relatively short
treatment duration of 12 weeks, the median reduction
in Nail Psoriasis Severity Index (NAPSI) score was 57%.
Clearance of psoriasis of the nails was increasing in those
patients who continued adalimumab up to week 20. The
NAPSI improvements were independent of other changes in
skin assessment measures and occurred regardless of joint
response status [5].
Etanercept is a TNFα receptor fusion protein adminis-
tered subcutaneously, which binds with and antagonizes the
action of TNFα. In one post hoc analysis, etanercept 25mg
twice weekly produced a mean reduction in NAPSI score
of 51% after 54 weeks in 711 patients with psoriasis, 80%
of whom had nail involvement [6]. In another retrospective
studyof66patientstreatedwithetanerceptat25mgor50mg
twice weekly at intermittent intervals over a period of 3.4
years, nail involvement improved signiﬁcantly in each of the
treatment cycles [7].
Ustekinumab is a fully human anti-IL-12/-23 mono-
clonal antibody that binds with high speciﬁcity and aﬃnity
to the shared p40 protein subunit of the cytokines IL-12 and
IL-23,blockingthediﬀerentiationandexpansion ofT-helper
(Th)1 and Th17 populations. It has recently been approved
in the USA, Europe and Canada for the treatment of
moderate to severe plaque psoriasis. Recently, ustekinumab
has also been reported as an eﬀective therapeutic alternative
in nail psoriasis [8].
Inﬂiximab is a chimeric monoclonal antibody that in-
hibits TNFα and is administered intravenously. At the
present time, the best evidence for the eﬃcacy of a TNFα
inhibitor in nail psoriasis comes from a phase III, multicen-
tre, double-blind, placebo-controlled trial designed to eval-
uate long-term eﬃcacy and safety of inﬂiximab in patients
with moderate to severe plaque psoriasis. The primary end-
pointof thestudy was theproportion ofpatients achieving at
least 75% improvement in Psoriasis Area and Severity Index
(PASI) compared with baseline. The percentage improve-
ment in NAPSI at weeks 10, 24, and 50 was also speciﬁcally
investigated. In this well-controlled trial, inﬂiximab resulted
in complete clearing of nail psoriasis in 6.9% of patients
within 10 weeks, rising to 26.4% after 24 weeks, and 44.7%
after50weeks. Nailclearancewasobservedin1.7%and5.1%
of patients at weeks 10 and 24 in placebo recipients, but thisCase Reports in Medicine 3
increased to 34.5% at week 38 and to 48.2% at week 50 after
the patients had switched to inﬂiximab [2, 9]. Inﬂiximab
is one of the most extensively studied biological agents in
dermatological practice and is considered by many to be the
most eﬀective treatment for nail psoriasis to date [10, 11].
No drug is completely safe, and several safety issues should
be considered. However, cumulative evidence indicates that
treatmentwithinﬂiximabissafeandwelltolerated,especially
if physicians are thoughtful in diagnosing infections and
infusion reactions early [12]. In our patient, inﬂiximab
showed remarkable and rapid eﬀectiveness in the treatment
of psoriatic nail disease. In addition, the present case illu-
strates the need to further evaluate biological therapies and
theircosteﬀectiveness,especiallyasﬁrst-line systemic agents,
for the treatment of severe psoriatic nail disease. We believe
that inﬂiximab may represent a treatment of choice for the
many patients with this distressing condition.
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